Comparability:
  Cell Therapy:
    General:
      US (FDA):
        Guidance Summary:
          - Risk-based analytical matrix with predefined decision rules; scale to phase and impact.
        Suggested next steps:
          - Freeze decision tree, sample size, margins; simulate outcomes; map to CTD.
      EU (EMA):
        Guidance Summary:
          - Convergent with FDA; emphasize predefined rules and statistical justification.
        Suggested next steps:
          - Confirm EU-acceptable statistics/margins and mapping to MAA.
